- Home
- OMCL vs RCKT Comparison
OMCL vs RCKT Comparison
Compare OMCL & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMCL
- RCKT
- Stock Information
- Founded
- OMCL 1992
- RCKT 1999
- Country
- OMCL United States
- RCKT United States
- Employees
- OMCL N/A
- RCKT N/A
- Industry
- OMCL Computer Manufacturing
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- OMCL Technology
- RCKT Health Care
- Exchange
- OMCL Nasdaq
- RCKT Nasdaq
- Market Cap
- OMCL 1.3B
- RCKT 264.0M
- IPO Year
- OMCL 2001
- RCKT N/A
- Fundamental
- Price
- OMCL $29.87
- RCKT $3.02
- Analyst Decision
- OMCL Buy
- RCKT Buy
- Analyst Count
- OMCL 6
- RCKT 13
- Target Price
- OMCL $44.83
- RCKT $18.50
- AVG Volume (30 Days)
- OMCL 456.5K
- RCKT 4.0M
- Earning Date
- OMCL 07-31-2025
- RCKT 08-04-2025
- Dividend Yield
- OMCL N/A
- RCKT N/A
- EPS Growth
- OMCL N/A
- RCKT N/A
- EPS
- OMCL 0.45
- RCKT N/A
- Revenue
- OMCL $1,135,755,000.00
- RCKT N/A
- Revenue This Year
- OMCL $3.84
- RCKT N/A
- Revenue Next Year
- OMCL $4.07
- RCKT N/A
- P/E Ratio
- OMCL $65.48
- RCKT N/A
- Revenue Growth
- OMCL 3.00
- RCKT N/A
- 52 Week Low
- OMCL $22.66
- RCKT $2.19
- 52 Week High
- OMCL $55.75
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- OMCL 53.16
- RCKT 45.25
- Support Level
- OMCL $28.81
- RCKT $2.76
- Resistance Level
- OMCL $30.55
- RCKT $2.96
- Average True Range (ATR)
- OMCL 0.82
- RCKT 0.20
- MACD
- OMCL 0.08
- RCKT 0.16
- Stochastic Oscillator
- OMCL 75.61
- RCKT 88.57
About OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.